Electronic health record alerts to prompt kidney and heart-protecting treatments in type 2 diabetes
Tests doctor alerts that prompt kidney and heart treatments in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
Key facts
- Where
- Dallas and Plano, United StatesSee the 2 sites
Where in United States
- Baylor Scott and White HealthDallas, United StatesNo longer taking part
- Baylor Scott and White, Advanced Heart CarePlano, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Baylor Research Institute
- Trial code
- NCT07605390
- Record updated
- 15 October 2026
- Original description
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria.Read full original descriptionShow less
RAPID-CKM: RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care.
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria.
The main question it aims to answer is:
• Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care?
Researchers will compare an Epic in-basket clinician notification strategy with usual care.
In the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.
Inclusion: Adults aged ≥18 years; Diagnosis of type 2 diabetes mellitus; Receiving outpatient care within Baylor Scott \& White Health; At least 1 outpatient encounter within the preceding 12 months; Confirmed albuminuria (UACR >30 mg/g); Eligible for one or more guideline-directed CKM therapies based on - prespecified clinical criteria and EHR review.
Exclusion: Contraindication or documented intolerance to all eligible guideline-directed CKM therapies; Contraindicated drug interactions (e.g., strong CYP3A inhibitors with finerenone); Other guideline- or labeling-based contraindications to therapy initiation; Type 1 diabetes mellitus; Hyperkalemia or elevated baseline serum potassium precluding safe therapy initiation; Advanced kidney dysfunction below recommended initiation thresholds for SGLT2i or finerenone.